US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Genomics Immunology and Healthcare ETF

40.97

-0.5072-1.22%

Volume:17.52K

Turnover:715.15K

Market Cap:256.08M

PE:- -

High:40.97

Open:40.81

Low:40.64

Close:41.48

52wk High:41.49

52wk Low:22.12

Shares:6.25M

Float Shares:6.25M

Volume Ratio:0.83

T/O Rate:0.28%

Dividend:0.28

Dividend Rate:0.69%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Cullinan Climbs as Lung Cancer Drug Meets Late-Stage Trial Goal

CRISM Therapeutics Clears Key Step to Begin Phase II Glioblastoma Trial

BofA Securities Boosts Targets on Chinese CXO Players as Strong Biotech Funding Fuels R&D

Bank of America Securities Raises Targets for Chinese CXO Firms on Strong Biotech Funding

Outlook Therapeutics Ends ATM Prospectus Amid Ongoing Risks

Moderna Inc. Stock Rises 5.1%, Outperforms Peers

Press Release: Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update

Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/IDNA/news?page=13"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IDNA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDNA\",,,,,undefined,":{"symbol":"IDNA","market":"US","secType":"STK","nameCN":"iShares Genomics Immunology and Healthcare ETF","latestPrice":40.9728,"timestamp":1787754003843,"preClose":41.48,"halted":0,"volume":17522,"delay":0,"changeRate":-0.012227579556412668,"floatShares":6250000,"shares":6250000,"eps":0,"marketStatus":"Trading","change":-0.5072,"latestTime":"08-26 10:20:39 EDT","open":40.8072,"high":40.9728,"low":40.6414,"amount":715146.640186,"amplitude":0.007989,"askPrice":40.97,"askSize":200,"bidPrice":40.76,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787774400000},"marketStatusCode":2,"adr":0,"exchange":"ARCA","adjPreClose":41.48,"sharesOutstanding":5100000,"nav":39.56427,"aum":247276687.5,"dividendRate":0.006875,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":41.2093,"preClose":41.48,"latestTime":"09:27 EDT","volume":16,"amount":665.699408,"timestamp":1787750854149,"change":-0.2707,"changeRate":-0.006526,"amplitude":0.04317},"postHourTrading":{"tag":"盘后","latestPrice":41.48,"preClose":41.48,"latestTime":"19:38 EDT","volume":175,"amount":7299.68,"timestamp":1787701127157,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.833451,"impliedVol":0.099,"impliedVolPercentile":0.1673},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDNA\",,,,,undefined,":{"symbol":"IDNA","floatShares":6250000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.833451,"shares":6250000,"dividePrice":0.2817,"high":40.9728,"amplitude":0.007989,"preClose":41.48,"low":40.6414,"week52Low":22.12,"pbRate":"--","week52High":41.49,"institutionHeld":0,"latestPrice":40.9728,"committee":-0.333333,"eps":0,"divideRate":0.006875,"volume":17522,"delay":0,"ttmEps":0,"open":40.8072,"prevYearClose":26.19,"prevWeekClose":40.08,"prevMonthClose":32.33,"prevQuarterClose":33.75,"fiveDayClose":40.75,"twentyDayClose":32.1477,"sixtyDayClose":29.32},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IDNA\",params:#limit:5,,,undefined,":[{"date":"2026-06-15","symbol":"IDNA","amount":0.125421,"announcedDate":"2026-06-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2025-12-16","symbol":"IDNA","amount":0.155456,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2025-06-16","symbol":"IDNA","amount":0.152909,"announcedDate":"2025-06-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-16","defaultRemindTime":1750080600000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-20","payableDate":"2025-06-16","currency":"USD","dateTimestamp":1750046400000,"payDate":"2025-06-20"},{"date":"2024-12-17","symbol":"IDNA","amount":0.11105,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2024-06-11","symbol":"IDNA","amount":0.11144,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-11","defaultRemindTime":1718112600000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-17","payableDate":"2024-06-11","currency":"USD","dateTimestamp":1718078400000,"payDate":"2024-06-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IDNA\",market:\"US\",,,undefined,":[{"executeDate":"2019-12-16","recordDate":"2019-12-17","paymentDate":"2019-12-20","value":0.237063,"currency":"USD"},{"executeDate":"2020-06-15","recordDate":"2020-06-16","paymentDate":"2020-06-19","value":0.083667,"currency":"USD"},{"executeDate":"2020-12-14","recordDate":"2020-12-15","paymentDate":"2020-12-18","value":0.036209,"currency":"USD"},{"executeDate":"2021-06-10","recordDate":"2021-06-11","paymentDate":"2021-06-16","value":0.052145,"currency":"USD"},{"executeDate":"2021-12-13","recordDate":"2021-12-14","paymentDate":"2021-12-17","value":0.256358,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IDNA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IDNA\",pageSize:20,pageCount:13,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659130742","title":"Cullinan Climbs as Lung Cancer Drug Meets Late-Stage Trial Goal","url":"https://stock-news.laohu8.com/highlight/detail?id=2659130742","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659130742?lang=en_us&edition=fundamental","pubTime":"2026-08-13 17:39","pubTimestamp":1786613984,"startTime":"0","endTime":"0","summary":"BUZZ-Cullinan climbs as lung cancer drug meets late-stage trial goal** Shares of Cullinan TherapeuticsCGEM.Orise 6% to $20.77 premarket** Cullinan says its experimental cancer drug, zipalertinib, when","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL4N44A0QA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD","LU0320765992.SGD","IE00BJJMRZ35.SGD","IE0009354923.USD","LU0889565916.HKD","CGEM","IE00BFTCPJ56.SGD","IDNA","BBH","CANC","IE00BJT1NW94.SGD","BK4139","IE00B2B36J28.USD","IE00B4R5TH58.HKD","IE0002141913.USD","LU0109394709.USD","PTH","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659613658","title":"CRISM Therapeutics Clears Key Step to Begin Phase II Glioblastoma Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2659613658","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659613658?lang=en_us&edition=fundamental","pubTime":"2026-08-13 14:12","pubTimestamp":1786601532,"startTime":"0","endTime":"0","summary":"Amur Minerals ( ($GB:CRTX) ) has shared an announcement. CRISM Therapeutics has completed the Site Initiation Visit at its lead NHS clinical trial ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/crism-therapeutics-clears-key-step-to-begin-phase-ii-glioblastoma-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/crism-therapeutics-clears-key-step-to-begin-phase-ii-glioblastoma-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","MEDX","BK4539","HYLG","BK4139","LENZ","GDOC","IDNA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155684243","title":"BofA Securities Boosts Targets on Chinese CXO Players as Strong Biotech Funding Fuels R&D","url":"https://stock-news.laohu8.com/highlight/detail?id=1155684243","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155684243?lang=en_us&edition=fundamental","pubTime":"2026-08-13 12:50","pubTimestamp":1786596641,"startTime":"0","endTime":"0","summary":"BofA Securities has released a report indicating that the Chinese CXO sector is poised to benefit from robust biotech venture capital funding. The bank notes that strong financing in the first half...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348766576.USD","WX","LU1719994722.HKD","LU1046422090.SGD","LU1997244956.HKD","LFSC","LU0052750758.USD","LU2328871848.SGD","XBIX","BK1141","LU0320764599.SGD","MEDI","LU1997245094.SGD","PSIL","BK0216","LU0348767384.USD","LU0700851271.USD","LU1969619763.USD","LU1251922891.USD","02359","LU1979443071.USD","LU2495084118.USD","IDNA","LU1934453819.USD","LU2242644610.SGD","SMCO","603259","IE00BPRC5H50.USD","LU1303224171.USD","LU2488822045.USD","BK1576","LU1997245177.USD","BK1583","IE00B5MMRT66.SGD","LU2125910500.SGD","LU1808992512.USD","CXO","BBC","LU0708995583.HKD","LU1770034418.SGD","FHLC","IBRN","161027","SURI","LU2045819591.USD","BMED","PSCH","LU0611395673.USD","APXH","IE00B543WZ88.USD","LU0456842615.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111112440","title":"Bank of America Securities Raises Targets for Chinese CXO Firms on Strong Biotech Funding","url":"https://stock-news.laohu8.com/highlight/detail?id=1111112440","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111112440?lang=en_us&edition=fundamental","pubTime":"2026-08-13 10:35","pubTimestamp":1786588544,"startTime":"0","endTime":"0","summary":"A report from Bank of America Securities indicates that Chinese CRO/CDMO companies are poised to benefit from robust first-half funding in the global and Chinese biotech sectors, along with active...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WX","BK1521","LFSC","LU0052750758.USD","LU0588546209.SGD","LU0348825331.USD","LU0181495838.USD","MEDI","LU2039709279.SGD","LU0348767384.USD","IE00B0JY6N72.USD","603259","LU1303224171.USD","LU0456827905.SGD","IE00B5MMRT66.SGD","LU2125910500.SGD","LU0128526141.USD","LU1808992512.USD","LU0979878070.USD","LU0823426308.USD","LU2045819591.USD","LU0326950275.SGD","PSCH","LU3063872942.SGD","SG9999002562.SGD","APXH","LU0456846285.SGD","LU1997244956.HKD","XBIX","LU0320764599.SGD","BK0216","LU0700851271.USD","LU0516422440.USD","LU1979443071.USD","IDNA","03759","LU2488822045.USD","KURE","LU1997245177.USD","LU0348735423.USD","BK1610","LU0029874061.USD","LU0051755006.USD","LU1770034418.SGD","LU0327786744.USD","IBRN","161027","LU0516423091.SGD","LU0516422952.EUR","LU0823426480.USD","IE00B543WZ88.USD","LU0456842615.SGD","LU0348766576.USD","LU0307460666.USD","LU1046422090.SGD","LU0043850808.USD","LU2328871848.SGD","LU0516423174.USD","BK1141","LU0417516738.SGD","LU1997245094.SGD","BK1589","LU0572944931.SGD","LU1242518931.SGD","LU1688375341.USD","LU0516422366.SGD","LU0819121731.USD","LU0140636845.USD","BK1583","LU1794554557.SGD","BBC","LU0708995583.HKD","02269","SURI","BMED","LU0611395673.USD","SG9999002463.SGD","LU1242518857.USD","LU0359202008.SGD","LU1880383366.USD","LU1719994722.HKD","LU1720050803.USD","LU0856984785.SGD","PSIL","LU1969619763.USD","LU1251922891.USD","02359","LU2495084118.USD","LU1934453819.USD","SMCO","IE00BPRC5H50.USD","BK1576","LU0359201612.USD","LU0417516902.SGD","CXO","FHLC","LU0039217434.USD","LU2242644610.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659926188","title":"Outlook Therapeutics Ends ATM Prospectus Amid Ongoing Risks","url":"https://stock-news.laohu8.com/highlight/detail?id=2659926188","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659926188?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:37","pubTimestamp":1786567029,"startTime":"0","endTime":"0","summary":"The latest update is out from Outlook Therapeutics ( ($OTLK) ). On July 24, 2026, Outlook Therapeutics announced U.S. FDA approval of LYTENAVA (bev...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/outlook-therapeutics-ends-atm-prospectus-amid-ongoing-risks?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/outlook-therapeutics-ends-atm-prospectus-amid-ongoing-risks?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GDOC","GNMX","BK4139","IDNA","FRTY","TECB","NVIB","IBB","LENZ","IEIH","IYH","MRNX","XLVX","BMED","BK4007","RSPH","LFSC","MRNY","BK4585","LABU","SYNB","BBP","PSCH","TBXU","MEDI","PINK","BK4539","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659188699","title":"Moderna Inc. Stock Rises 5.1%, Outperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2659188699","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659188699?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:34","pubTimestamp":1786566840,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Moderna Inc. rallied 5.1% to $63.67 on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index rising 0.5% to 26,588.49 and the Dow Jones Industrial Average remaining mostly unchanged at 53,770.27.This was the stock's fourth consecutive day of gains.Moderna Inc. closed 25.6% below its 52-week high of $85.60, which the company reached on July 6th.The stock outperformed some of its peers, as Johnson & Johnson rose 0.4% to $260.86, Pfizer Inc. fell 1.2% to $26.31, and Gilead Sciences Inc. rose 0.07% to $135.87.Trading volume totaled 6.0 million, compared to the 50-day average of 7.3 million.Data source: Dow Jones Market Data, FactSet","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","MRNA","MRNX","LU1674673691.USD","LU1934455194.USD","LU2087621335.USD","MEDI","IE00BKVL7J92.USD","LU1585245621.USD","LU2112291526.USD","BK4532","IDNA","BK4588","LU1430594728.SGD","BK4501","LU1037948541.HKD","BK4550","BBH","LU0823416689.USD","TMED","LU1057294990.SGD","IE00B19Z3581.USD","IE0002270589.USD","IE00BSNM7G36.USD","LU0889565916.HKD","BMED","GNOM","LU2324357040.USD","WDNA","LU1037948897.HKD","LU1023059063.AUD","SG9999015978.USD","LU1674673428.USD","BK4139","BIB","TBXU","LGHT","GILD","LU0882574055.USD","LU1061106388.HKD","LU0965508806.USD","BK4551","LU0289739699.SGD","BK4566","IBB","BK4585","MRNY","LU1066051498.USD","IE00BZ1G4Q59.USD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659907259","title":"Press Release: Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659907259","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659907259?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:05","pubTimestamp":1786565100,"startTime":"0","endTime":"0","summary":"-- On track for September 2026 top-line results from Phase 2b clinical trial.  evaluating laromestrocel as a potential adjunct treatment for. hypoplastic left heart syndrome , a rare pediatric disease and. -- Longeveron selected as a Finalist and Milestone 2 Awardee for the XPRIZE. Healthspan competition based on published clinical trial results which. indicated laromestrocel increased 6-minute walk distance in patients with. -- Three new independent Directors join Longeveron's Board of Directors. laromestrocel as a potential adjunct therapy for HLHS are anticipated in. -- In May, the Company announced that the U.S. Food and Drug Administration.  held a Type C meeting in late March 2026 focused on the ELPIS II. Phase 2b clinical trial and upcoming data readout.-- Also in May, the Company announced that the independent Data Monitoring. Committee  completed its final prespecified data review for ELPIS II. Phase 2b clinical trial . The DMC performed a risk-benefit. assessment, indicated n","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","GDOC","BK4232","DMC","LGVN","BK4022","BK4081","NVIB","BK4139","R","BK4132","AD","IND","BK4189","IDNA","HYLG","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658290503","title":"Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2658290503","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658290503?lang=en_us&edition=fundamental","pubTime":"2026-08-12 23:02","pubTimestamp":1786546971,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals  has multiple potential catalysts coming from its portfolio that provide a net positive risk-reward profile for the company, RBC Capital Markets said in a Wednesday note.The company is expected to present results from its phase 1 study of VX-828 in patients with cystic fibrosis in H2, with a positive readout potentially strengthening its competitive advantage in the space, RBC analysts said.Favorable data will likely result in modest upside, while unfavorable data will likely lead to little downside, the analysts added.Meanwhile, approval by the US Food and Drug Administration for Vertex's povetacicept in immunoglobulin A nephropathy, with a PDUFA date of Nov. 30, 2026, is likely due to strong interim phase 3 results, the analysts said.They said that the drug's differentiated profile could make it the preferred choice of most doctors.With Sionna Therapeutics  failing to demonstrate significant sweat chloride improvements as an add-on to Trikafta, one of the more ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0058720904.USD","VRTX","BK4585","SGXZ57979304.SGD","LU0566484027.USD","BBH","IE00B19Z3B42.SGD","IE00B19Z9P08.USD","IE00BJT1NW94.SGD","BIB","SION","IDNA","LU0061475181.USD","BK4023","LU0109394709.USD","BK4532","LU1815336091.USD","TBXU","BK4139","LU0417517546.SGD","IE00BJJMRZ35.SGD","LU1674673691.USD","IBBQ","LU2417539215.USD","IE00B19Z3581.USD","IE00B19Z9Z06.USD","LU2237438978.USD","LU2324357040.USD","PBE","IE00B2B36J28.USD","LU2362541273.HKD","SG9999013999.USD","LU1069344957.HKD","GNMX","BK4567","IBB","IE00BZ9MQY76.HKD","LU2362540622.SGD","LU2456880835.USD","IE00BFTCPJ56.SGD","LU1559883803.SGD","LU1430594728.SGD","LU2362541513.USD","LU1093756325.SGD","VERX","LU1778281490.HKD","LU0079474960.USD","BK4588","BK4533","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":13,"pageCount":13,"totalSize":248,"code":"91000000","status":"200"}]}}